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Abstract
Objectives To compare maximum tumour diameter (MTD)
and gross tumour volume (GTV) measurements between T2-
weighted (T2-w) and diffusion-weighted (DWI) MRI in squa-
mous cell carcinoma of the anal canal (SCCA) and assess
sequence impact on tumour (T) staging. Second, to evaluate
interobserver agreement and reader delineation confidence.
Methods The staging MRI scans of 45 SCCA patients (25
females) were assessed retrospectively by two independent
radiologists (0 and 5 years’ experience of anal cancer MRI).
MTD and GTV were delineated on both T2-w and high-b-
value DWI images and compared between sequences; T stag-
ing was derived from MTD. Interobserver agreement was
assessed and delineation confidence scored (1 to 5) by each
observer.
Results GTVand MTD were significantly and systematically
lower on DWI versus T2-w sequences by 14.80%/9.98%
(MTD) and 29.70%/12.25% (GTV) for each reader, respec-
tively, causing T staging discordances in approximately a
quarter of cases. Bland-Altman limits of agreement were
narrower and intraclass correlation coefficients higher for
DWI. Delineation confidence was greater on DWI: 40/42
cases were scored confidently (4 or 5) by each reader, respec-
tively, versus 31/36 cases based on T2-w images.
Conclusions Sequence selection affects SCCAmeasurements
and T stage. DWI yields higher interobserver agreement and
greater tumour delineation confidence.
Key Points
• MTD and GTV measurements are significantly lower on
DWI than on T2-w MRI.
• Such differences cause T staging discordances in up to a
quarter of cases.
•DWI results in higher agreement between inexperienced and
experienced observers.
• DWI offers greater tumour delineation confidence to inex-
perienced readers.
Keywords Anus neoplasms .Magnetic resonance imaging .
Neoplasm staging . Radiotherapy, image-guided . Diffusion
magnetic resonance imaging
Abbreviations
DWI Diffusion-weighted imaging
GTV Gross tumour volume
IMRT Intensity-modulated radiotherapy
MTD Maximum tumour diameter
SCCA Squamous cell carcinoma of the anus
SIBR Simultaneous integrated boost radiotherapy
T2-w T2 weighted
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Introduction
The incidence of squamous-cell carcinoma of the anus
(SCCA), commonly referred to as anal cancer, has increased
steadily over the past 4 decades in the Western world [1, 2].
The standard-of-care treatment for non-metastatic SCCA is
definitive chemoradiation (CRT) [3]: its aim is to eradicate
the tumour while preserving anal sphincter function.
Magnetic resonance imaging (MRI) is recommended in
Europe as the imaging modality of choice for loco-regional
staging of SCCA [3] and has a growing role in radiation ther-
apy planning [4]. High-resolution T2-weighted (T2-w) se-
quences, obtained in the appropriate planes, provide detailed
anatomical depiction of the anorectal region thanks to optimal
soft-tissue contrast [5–8] and are in principle best suited for
accurate target volume delineation.
Diffusion-weighted imaging (DWI) is now routinely in-
cluded in body MRI protocols in most European oncological
imaging centres: it has been shown to aid the diagnosis and
response assessment of a variety of malignancies [9–13] and
to allow the detection of small tumours in the pelvis [14].
Hypercellular tumours restrict water diffusion in the
extracellular-extravascular space and typically stand out as
bright lesions on a ‘dark’ background of suppressed signal
on high b-value sequences, facilitating detection and delinea-
tion. Anal cancers typically appear restricted on DWI [15].
Maximum tumour diameter (MTD) is an important mea-
surement in anal cancer, as it determines the T stage according
to current TNM (7th ed.) criteria [16] (Table 1). Gross tumour
volume (GTV), defined as the gross primary anal tumour vol-
ume, forms the basis to calculate clinical and planning target
volumes, which in turn determine radiotherapy dose distribu-
tion. Accurate GTV delineation is critical to the delivery of
intensity-modulated radiotherapy (IMRT), which produces
steep dose gradients and allows dose escalation to smaller
high-risk target volumes (simultaneous integrated boost radio-
therapy, SIBR) [17].
This study aimed to investigate the extent to which MRI
measurements, specifically MTD and GTV, differ between
anatomical T2-w and functional DWI sequences, as the impli-
cations for staging and treatment planning are clearly relevant
to clinical practice. Second, it aimed to measure interobserver
agreement for MTD and GTV as well as compare tumour
detection confidence between observers with differing levels
of interpretation experience.
Materials and methods
A review board waiver was granted for this retrospective anal-
ysis of anonymised imaging data acquired as part of normal
clinical care. Fifty patients with biopsy-proven SCCA under-
going pelvic MRI for locoregional staging prior to definitive
chemoradiation were identified from the picture archiving and
communication system (PACS) of two tertiary-referral cancer
centres, between July 2007 and June 2015. Cases were ex-
cluded if the tumour was incompletely imaged on either T2-w
sequences or DWI (n = 3); the primary tumour was deemed
undetectable on either sequence by secondary consensus read-
ing (n = 2); the presence of MRI image artefact precluded
accurate tumour measurements (n = 0).
Imaging protocol
Patients were scanned supine on one of three 1.5-T MRI scan-
ners (Magnetom Avanto or Aera, Siemens Healthineers,
Erlangen, Germany) using a pelvic phased array coil. The ex-
amination protocol included a T2-w sagittal turbo spin echo
(TSE) sequence covering the pelvis (typical acquisition param-
eters: TR/TE = 4430/100 ms, NEX = 2, ST = 3 mm, gap 0.3
mm, FOV 250 × 250 mm, matrix = 307 × 384), a T1-w axial
TSE sequence for pelvic nodal detection (TR/TE = 552/11 ms,
NEX = 1, ST = 5 mm, gap = 1.5 mm, FOV = 300 × 300 mm,
matrix = 240 × 320), a T2-w axial TSE sequence of the pelvis
(TR/TE = 4590/101 ms, NEX = 1, ST = 5 mm, gap = 1.5 mm,
FOV = 300 × 300, matrix = 307 × 384) and high-resolution
small-field-of-view T2-w TSE sequences perpendicular and
parallel to the anal canal (TR/TE = 6530/104 ms, NEX = 2,
ST = 3 mm, gap = 0.3 mm, FOV = 200 × 200, matrix = 512 ×
512). DWI consisted of a single shot spin echo-echo planar
imaging (SE-EPI) axial diffusion-weighted sequence (TR/TE
= 5900/68 ms, NEX = 4, ST = 5 mm, gap = 1.5 mm, FOV =
300 × 300, matrix = 116 × 154) encompassing the pelvis with
three b-values in all cases (0, 100, 800 s/mm2). Vendor-
generated apparent diffusion coefficient (ADC) maps were au-
tomatically created at the time of acquisition. Patients did not
undergo any additional preparation prior to the examination.
MTD and GTV measurements
A third-year radiology resident (RM) with 1 year prior MRI
experience but no previous experience in staging SCCA and a
subspecialty gastrointestinal radiology fellow (DP) with 5
years’ experience of staging gastrointestinal cancers evaluated
Table 1 SCCA primary tumour (T) staging criteria according to the
AJCC Cancer Staging Manual, 7th edition [16]
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour ≤2 cm in greatest dimension
T2 Tumour >2 cm and ≤5 cm in greatest dimension
T3 Tumour >5 cm in greatest dimension
T4 Tumour of any size invading adjacent organs
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the scans independently using all available sequences.
Anonymised scans were downloaded from the local PACS
onto a standalone workstation (iMac®, Apple Inc., CA,
USA) and presented in randomised order in OsiriX v.7.5.1
(OsiriX Foundation, Geneva, Switzerland); readers were
blinded to all clinical information. GTV delineation was per-
formed separately on high-resolution axial-oblique T2-w and
axial high-b-value (b = 800) DWI sequences, with a 1-week
interval between the two reading sessions; DWI was read in
conjunction with apparent diffusion coefficient (ADC) maps.
Free-hand perilesional regions of interest (ROIs) were drawn
on each slice with visible tumour and GTVs obtained by com-
puting the ROI volumes. MTDs were obtained from sagittal
T2-w sequences and sagittal reformats of axial high-b-value
DWI, choosing the plane yielding the longest measurement on
a case-by-case basis and using straight-line measurements
(Fig. 1).
GTV confidence score
Each observer rated their confidence at contouring each tu-
mour GTVon both T2-w and DWI sequences using a 5-point
scale (1, no tumour boundaries identified with confidence; 2,
tumour boundaries identified with confidence on a minority of
images (< 25%); 3, tumour boundaries identified with confi-
dence on approximately half of the images; 4, tumour bound-
aries identified confidently on most images (> 75%); 5, tu-
mour boundaries identified confidently on all images).
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics,
version 23. Mean values between the two readers’ MTD and
GTVmeasurements were used in T2-w vs. DWI comparisons;
measurements were compared using the independent samples
t-test and correlated using Pearson’s r. Interobserver agree-
ment between the readers’ MTD and GTV measurements
was assessed using the 95% Bland-Altman limits of agree-
ment [18]. Intraclass correlation coefficients (two-way
consistency model, absolute agreement type, average
measures) were also calculated. A P value < 0.05 was taken
to represent statistical significance for all analyses.
Results
The final cohort consisted of 45 patients, 25 females and 20
males, with a mean age of 62 years (standard deviation, 12.5;
Fig. 1 Anorectal SCCA. High-
resolution T2-w axial-oblique im-
age at the level of the anorectal
junction (top left): lesion
contouring is challenging consid-
ering the suboptimal contrast res-
olution between tumour and ad-
jacent mucosa. Same-level high
b-value axial DWI (top right): the
hyperintense lesion can be clearly
outlined against the suppressed
signal of surrounding healthy tis-
sue. T2-w sagittal image used for
MTD measurement (bottom left).
Corresponding sagittal reformat
of high b-value DWI, also used
for MTD measurement (bottom
right)
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range, 37-84 years) and corresponding to 45 MRI data sets
analysed by each observer.
MTD and GTV measurements
Reader-specific tumour diameters and volumes measured on
T2-w sequences and DWI are summarised in Table 2. GTV
and MTD measurements were significantly different between
T2-w and DWI for both observers (paired samples t-test P
values <0.001) (Table 2) and consistently lower on DWI
(Fig. 2) by percentage values ranging between 9.98% and
29.70% (Table 2). As a consequence, MTD-based tumour
(T) staging was discordant in 12 cases based on inexperienced
observer measurements and in 10 cases based on experienced
measurements (Fig. 3). As expected, inter-sequence measure-
ments were strongly and significantly correlated, with r values
ranging between 0.875 and 0.987.
Interobserver agreement
Agreement was marginally superior on DWI for MTD. Mean
MTD difference (95% limits of agreement) between the two
readers was -0.46 (-2.89 to +1.97) cm on T2-w and -0.14 (-
2.38 to +2.10) cm on DWI. Agreement was considerably su-
perior on DWI for GTV. Mean GTV difference was -3.96 (-
17.91 to +9.97) cm3 on T2-w and 0.87 (-6.75 to +8.50) cm
3 on
DWI (Fig. 4). Intraclass correlation coefficients, reported in
Table 3, were well above 0.8 (indicating excellent agreement)
but higher for DWI.
GTV confidence scoring
Tumours were outlined with greater confidence on DWI than
on T2-w sequences by both readers. This gap in confidence
was more substantial for the inexperienced reader: they
assigned a low confidence score (1 to 3) to 14 cases on T2-w
versus 5 cases for the experienced reader on DWI and a high
confidence score to 31 cases on T2-w versus 40 cases on DWI.
Full confidence score results are reported in Figs. 4 and 5.
Discussion
We found that tumour volumes and maximum diameters mea-
sured on functional DWI were significantly lower than those
measured on anatomical T2-w sequences.
Table 2 Reader-specific MTD and GTV measurements (mean, standard deviation and range), paired samples t-test P values and Pearson correlation
test r and P values
Observer 1 (inexperienced) Observer 2 (experienced)
MTD (cm) GTV (cm3) MTD (cm) GTV (cm3)
Mean SD Range Mean SD Range Mean SD Range Mean SD Range
T2-w 5.88 2.14 1.36–10.93 24.95 23.67 0.89–110.84 5.41 2.07 1.46–9.58 20.98 20.94 0.70–95.04
DWI b800 5.01 1.99 1.16–9.38 17.54 18.30 0.16–79.99 4.87 2.24 0.79–10.83 18.41 20.10 0.13–95.15
Relative
change
−14.80% −29.70% −9.98% −12.25%
t-test P <0.001 <0.001 <0.001 <0.001
Correlation r 0.875 0.949 0.906 0.987
Correlation P <0.001 <0.001 <0.001 <0.001
Fig. 2 Mean MTD (cm) and GTV (cm3) measurements on T2-w versus DWI sequences, visualised case by case. Both measurements were systemat-
ically lower on DWI than on T2-w
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While no previous paper has investigated anal cancer, sim-
ilar differences have been found in primary rectal cancer
[19–21]: Curvo-Semedo et al. reported median pre-treatment
tumour volumes of 18.0 cm3 on DWI versus 21.8 cm3 on T2-
w, a relative difference of 17.43%; similarly, Regini et al.
measured smaller GTVs on DWI, with relative differences
of 3.04% -7.62% not reaching statistical significance.
Squamous cell carcinomas are typically associated with
Fig. 3 Tumour (T) staging based on MTD measurements on T2-w versus DWI. Sequence selection affects T staging, particularly when the reader is
inexperienced (Observer 1)
Fig. 4 Interobserver agreement. Bland-Altman plots for MTD and GTV on T2-w versus DWI sequences: relative interobserver differences (mean
difference and 95% limits of agreement) are plotted against the mean value
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markedly impeded diffusion and display high signal intensi-
ties on DWI; adenocarcinomas, conversely, only appear mod-
erately restricted because of their glandular structure and pres-
ence of mucin [22]. This pathological difference is likely to
contribute to smaller DWI measurements in anal cancer com-
pared to T2-w sequences.
Tumour greatest dimension is the only measurement deter-
mining T stage in SCCA according to AJCC TNM criteria
[16]: based on our results, tumours bordering 2 cm and 5 cm
in MTD (corresponding to T1/T2 and T2/T3 thresholds, re-
spectively) are prone to categorisation variability, depending
on both the reader and the sequence chosen for measurement:
approximately a fourth of cases in our series were assigned a
discordant T stage between T2-w and DWI sequences by both
the inexperienced and experienced observer. With the wider
implementation of personalised radiotherapy protocols, MTD
and, consequently, T stage may also affect the GTV to clinical
target volume (CTV) margin, the dose to the primary tumour
and the use of simultaneous boost; the PLATO (Personalising
Anal Cancer Radiotherapy Dose) protocol, for example, man-
dates an isocentric GTV-CTV margin of 10 mm for tumours
up to 4 cm in MTD versus 15 mm for larger tumours [23]. To
our knowledge, to date no other study has described the scale
of this potential modality-, sequence- and observer-dependent
variability and specific guidelines are still lacking on the
matter.
Accurate tumour delineation is critical to radiotherapy
planning. With the implementation of intensity modulated
radiotherapy (IMRT) in the treatment of SCCA, it has become
possible to escalate the dose to the target volume whilst main-
taining the same or reducing dose to the surrounding normal
tissues, resulting in steep dose gradients. To ensure appropri-
ate dose delivery, both tumour and normal tissues must be
delineated in 3D with high precision in reference to advanced
diagnostic imaging techniques, including functional imaging
[24]. The importance of access to high-quality diagnostic im-
aging has been illustrated by the US-based RTOG 0529 phase
II trial evaluating dose-painting IMRT in SCCA, in which the
gross tumour was inaccurately delineated in 21% of cases
[25].
MRI is recognised in Europe as the modality of choice for
locoregional staging of SCCA because of its high soft tissue
contrast and its ability to depict local tumour infiltration; most
clinical oncologists will refer to diagnostic MRI images at the
time of planning: these can be co-registered with planning CT
images used for dose calculation. The limiting factor in this
setting may be the lack of experience in MRI interpretation;
T2-w sequences represent the bedrock of pelvic MRI for de-
tailed anatomical interpretation but require an advanced level
of knowledge of the relevant cross-sectional anatomy. Signal
intensities of tumour, muscle, fat and bowel contents are often
very similar and can be challenging to tell apart with confi-
dence. We believe our results partly reflect the challenges of
distinguishing tumour from normal tissue in the anorectum on
anatomical T2-w sequences alone. Fourteen and nine cases
were assigned a low confidence score (1 to 3) by the inexpe-
rienced and experienced observer, respectively; these
corresponded to either small (T1/T2) tumours with irregular
margins and an infiltrative behaviour through the anal sphinc-
ter complex or anorectal junctional tumours surrounded by
mucosal oedema and/or luminal fluid (Fig. 1).
In this context, the typically bright appearance of SCCA
against a dark background on high b-value DWI facilitates
Table 3 Intraclass correlation coefficients (95% confidence intervals)
MTD GTV
T2-w 0.899 (0.803–0.946) 0.968 (0.915–0.985)
DWI b800 0.925 (0.863–0.959) 0.990 (0.918–0.994)
Fig. 5 Confidence scores. Both the inexperienced (Observer 1) and the experienced reader (Observer 2) outlined tumours confidently (scores of 4 to 5)
more frequently on DWI than on T2-w. The confidence gain with DWI is greater for the inexperienced observer
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tumour delineation based on our study results. DWI certainly
improved the confidence of both the inexperienced and expe-
rienced observer in outlining tumours in this study.
A drawback of the most commonly used single-shot echo-
planar-imaging (EPI)-based DWI sequence is that it is prone
to artefacts and susceptibility-related geometrical distortions,
potentially detrimental in the setting of radiotherapy planning.
These issues are being addressed through the development of
distortion-correction strategies [26] and the optimisation of
turbo spin echo (TSE)-based sequences [27]. In our high-b-
value DWI series, the most common cause for measurement
discrepancies between observers was the inclusion by the in-
experienced observer of susceptibility artefacts at the anal
verge (tissue-air interface), emphasising the importance of
taking the learning curve into account when approaching
DWI.
Regarding the potential implications of underestimating vs.
overestimating tumour length/volume, it is worth stressing
that the current research focus in patients with early disease
is radiotherapy dose de-escalation, given the low rates of
locoregional failure and significant toxicity at current dose
regimens [3, 23]. Conversely, patients with locally advanced
disease, 30% of whom experience locoregional failure, may
benefit from higher radiotherapy doses or sequential boosts by
means of IMRT [28, 29]. Applying these considerations to our
study series and assuming experienced measurements as ‘ac-
curate’, six cases would have been overstaged as T3
(advanced) disease by the inexperienced observer based on
T2 sequences alone; none understaged; only 2 based on
DWI (Fig. 3). Complementing T2 sequences with DWI, there-
fore, would seem more likely to save patients from radiother-
apy toxicity than compromise their outcome by size
underestimation.
This study has a number of limitations: its retrospective
nature meant that minor variations in the imaging acquisition
across different 1.5-T scanners could not be avoided; the se-
quences used for measurements and DWI b-values were nev-
ertheless consistent. We did not evaluate spatial concordance
and volume overlap between T2-w and DWI, as performed by
Burbach et al. for rectal cancer [30], though it would be inter-
esting to assess the entity of geometrical distortions in anal
cancer using conventional EPI-based DWI sequences. As
DWI was acquired as a 2D axial sequence with a 1.5-mm slice
gap, sagittal reformats yielded slightly blurred images with a
potential impact on MTD measurements: it is reassuring nev-
ertheless that the trend for smaller measurements on DWI was
maintained.
In summary, this study has shown that anal cancer MTD
and GTV measurements are consistently and significantly
lower on DWI than on T2-w sequences, with consequent
intersequence T staging discordances and potential implica-
tions for radiotherapy target volume delineation. This high-
lights the need for more specific guidelines on the subjects.
Based on these findings and our clinical experience we would
recommend the inclusion of DWI in anal cancer staging/
radiotherapy planning MRI protocols and its use alongside
anatomical sequences. DWI measurements resulted in higher
agreement between observers with differing levels of experi-
ence. DWI offered greater tumour delineation confidence over
T2-w sequences to the inexperienced observer and even to the
experienced in the case of small tumours infiltrating the anal
sphincter complex or at the anorectal junction.
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